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Abstract 
Interleukin-1β (IL-1β), a key cytokine driving neuroinflammation in the Central 
Nervous System (CNS), is enhanced in many neurological diseases/disorders, 
including but not limited to ischemic stroke, Parkinson’s disease, Amyotrophic 
Lateral Sclerosis, Huntington’s disease and Alzheimer’s disease. The dominant 
view is that IL-1β contributes to and/or sustains pathophysiological processes. 
However, other studies demonstrate that IL-1β can play an important role in 
neural protection and repair. It may do so by modifying astrocyte behavior. 
Indeed, studies from our laboratory demonstrate that IL-1β increases the 
synthesis and release of the antioxidant molecule glutathione (GSH) from 
astrocytes and that IL-1β-treated astrocytes show increased resistance to 
oxidative stress [1], a pathological process that leads to neural damage in the 
above-mentioned maladies. Given this, the overall goal of this thesis was to 
study the protective potential of IL-1β against oxidant injury in astrocytes, 
neurons and astrocyte and neurons in co-culture.  
We confirmed that IL-1β mediates an increase in extracellular GSH levels in 
cortical wild-type astrocytic (as shown by our laboratory earlier [1]) and mixed 
cultures but not neuronal culture. IL-1β-mediated GSH enhancement rendered 
protection to mixed culture against oxidative stress induced by the stressor tert-
butyl hydroperoxide (t-BOOH). GSH production and the resultant protection were 
blocked by the inhibition of GSH transport through Mrp1. Additionally, IL-1β failed 
to increase GSH or to provide protection against t-BOOH toxicity in chimeric 
 
 
  
cultures made using il1r1 null mutant astrocytes (lacking a functional IL-1R1 
receptor) indicating the necessity of astrocytic signaling for the observed 
phenomenon. Overall, these findings suggest that under certain conditions IL-1β 
may be an important stimulus for GSH production and consequent 
neuroprotection through astrocyte-specific signaling. 
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Chapter 1. Introduction 
1.1 IL-1β and Neuroinflammation 
Inflammation in the CNS (a.k.a. neuroinflammation) and elsewhere in the body is 
mediated by a number of soluble factors, including a group of secreted molecules 
termed cytokines. Inflammatory cytokines can contribute to either acute 
inflammation which is generally viewed as a protective/reparative response [2-4] 
or to chronic inflammation which is commonly considered deleterious to tissues 
harmful to impaired CNS [5-9].  Some cytokines, such as IL-1β, contribute to 
both [10-12]. This dissertation is directed at studying the potential protective 
effects of IL-1β against oxidant stress in central nervous system tissue 
neuroinflammation.  
1.1.1.  IL-1 family of cytokines 
IL-1β is a member of the canonical IL-1 family that consists of two agonists IL-1α 
and IL-1β, a naturally occurring receptor antagonist IL-1Ra, and two receptors 
(IL-1RI and IL-1RII) [13-15]. Currently this family has been extended with 
additional members added based on conservation of key amino acid sequences 
and similar three-dimensional structure [9, 16-18]. All ligands and receptors are 
expressed in the healthy CNS at low levels [19-21]. IL-1 has been shown to be 
produced by microglia [22, 23], astrocytes [24, 25], oligodendrocytes [26], and 
neurons [20, 27]. These same cell types are also capable of responding to the 
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cytokine [26, 28-30]. Further discussion will be limited to IL-1β, the key cytokine 
discussed in this thesis.  
Table 1: The IL-1 superfamily of cytokines (Figure adapted from [31]). 
New name Other Name Property 
IL-1F1 IL-1α Agonist 
IL-1F2 IL-1β Agonist 
IL-1F3 IL-1Ra Receptor antagonist 
IL-1F4 IL-18; IFN-γ-inducing factor Agonist 
IL-1F5 FIL1δ Anti-inflammatory 
IL-1F6 FIL-1ε Agonist 
IL-1F7 IL-1H4, IL-1ζ Anti-inflammatory 
IL-1F8 IL-1H2 Agonist 
IL-1F9 IL-1ε Agonist 
IL-1F10 IL-1Hy2 Receptor antagonist? 
IL-1F11 IL-33 Agonist 
 
1.1.2 IL-1β 
IL-1β is truly a pleiotropic cytokine and affects the innate as well as the acquired 
immune systems. The agonists are synthesized as precursor molecules without a 
signal peptide. After the removal of N-terminal amino acids by proteases, the 
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resulting peptides are called “mature” forms (See review [32]). The 31 kDa 
precursor form of IL-1β is biologically inactive and requires cleavage by a specific 
intracellular cysteine protease called IL-1β converting enzyme (ICE) or caspase 1 
[33]. The mature form of IL-1β is a 17.5 kDa protein. Although ICE cleaves the 
pro-ligands intracellularly, other proteases such as proteinase-3 can process the 
IL-1β precursor extracellularly into a mature ligand [34]. 
1.1.3 IL-1β Signaling 
IL-1β can bind to two receptors, the type I and type II, referred to as IL-1R1 and 
IL-1RII, respectively. Each has a large extracellular domain composed of a series 
of three immunoglobulin (Ig)-like motifs; however, only IL-1RI possesses a large 
intracellular Toll-like/IL-1 receptor (TIR) domain, which participates in the 
intracellular downstream signaling. At the surface, IL-1β forms a dimer with IL-
1RI and induces a conformational change: the Ig-like domains hook around the 
bound IL-1 molecule [35]. Following this, another protein known as the IL-1 
receptor accessory protein or IL-1RAcP binds to the IL-1RI/IL-1 complex, 
bringing together their Toll-like/IL-1 receptor (TIR) domains [36, 37]. After the 
recruitment of the IL-1/IL-1RI/IL-1RAcP complex, MyD88 (myeloid differentiation 
factor 88), a signaling molecule attaches to the complex [38]. This leads to the 
association with IL-1 receptor associated kinases (IRAK)-1 and IRAK-4 [37]. 
IRAK-1 and IRAK-4 when activated, can mediate downstream signaling events, 
which can result in the activation of the NF-κ B pathway [39-43], the p38 
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mitogen-activated protein (MAP) kinase pathway [44], the c-Jun N-terminal 
kinase (JNK) pathway [45] and the Src family of tyrosine kinases [46-48].  
IL-1RII, which lacks the intracellular signaling domain, is thought to function as a 
“decoy” receptor or negative regulator of IL-1β signaling [31]. The binding of IL-
1RII to IL-1β at the cell prevents the ability of the IL-1β to form a complex with 
the type I receptor and the accessory protein [49, 50]. Another proposed function 
of the decoy receptor is to form a trimeric complex of the ligand with the type II 
receptor and the accessory protein [51, 52].  
1.1.4 IL-1Ra 
IL-1Ra is a naturally occurring IL-1RI antagonist. It is a specific receptor 
antagonist for IL-1α and IL-1β. The binding of IL-1RI to IL-1RAcP is required for 
intracellular signaling and it is this association that is blocked by IL-1Ra [53-55]. 
1.1.5. IL-1β: Beneficial or inimical? 
Interestingly, IL-1α, IL-1β, and IL-1RI knockout mice show no gross physiological 
or developmental defects [56, 57]. And IL-1β alone, in the absence of additional 
CNS impairment, is not neurotoxic [2-4]. Despite this, many studies suggest that 
IL-1β is harmful to impaired CNS [5-9]. However, studies also suggest it to be 
neuroprotective [58-62]. Whether IL-1β is beneficial or inimical appears to 
depend on the concentration of the cytokine, status of surrounding cells and 
timing of release [59, 63-65]. The following is a description of a few paradigms in 
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which the laboratory has been studying the role of IL-1β that serves to illustrate 
the dichotomy described above. 
IL-1β and seizures: The incidence of convulsive seizures induced by the 
chemoconvulsant pentelyenetetrazol (PTZ) increases in null mutant mouse lines 
lacking the IL-1β ligand or the receptor IL-1R1 as compared to their respective 
wild-type littermate controls [66]. These results suggest that IL-1β serves as an 
endogenous modulator to suppress seizure generation.  
IL-1β and cerebral ischemia: IL-1RI null mutant mice are less susceptible than 
wild-type control mice to focal cerebral ischemic damage induced by reversible 
MCAO [67]. These studies complemented previous published work in 
experimental ischemia models showing that animals deficient in ICE/caspase 1 
had a reduction in IL-1β levels and a concomitant reduction in ischemic infarct 
volumes as compared to wild-type mice [68, 69]. Additionally, administration of 
an IL-1β neutralizing antibody improved outcomes following ischemia in rats [70]. 
Finally, intracerebroventricular administration and genetic overexpression of IL-
1Ra, the endogenous antagonist, before MCAO, is protective and reduces infarct 
size [3, 71-74]. Moreover, we have shown that IL-1β treatment enhances 
neuronal injury in a variety of neuronal injury models associated with energy 
deprivation [67, 75]. These studies demonstrate a predominantly negative effect 
of IL-1β in the setting of cerebral ischemia.  
IL-1β and oxidative stress: Oxidative stress is involved in conditions of critical 
injury to neurons and glia in the CNS. Reactive nitrogen and oxygen species 
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(RNOS) are part of the cascade that eventually lead to cell death [76]. A 
correlation between accumulation of ROS and an increase in IL-1β during 
oxidative stress has been demonstrated [77-79], suggesting RNOS production 
could increase IL-1β levels. In support, plasminogen-induced IL-1β production 
from microglia is reduced in the presence of the antioxidants trolox or N-acetyl-
cysteine (NAC) [80]. But of what consequence is this increase? We have found 
that IL-1β mediates a time-dependent increase in extracellular GSH levels 
production from cortical astrocyte cultures, suggesting both enhanced synthesis 
and export. Moreover, IL-1β treatment prevented the increase in ROS produced 
in astrocytes following exposure to peroxide. Further, the toxicity associated with 
this exposure was significantly attenuated following treatment with IL-1β [1]. 
These data point to a positive, protective role for IL-1β against oxidative stress. 
This result is of particular importance given the contributory role of oxidative 
stress to neuronal injury in the CNS disease/disorders.  
1.2. Oxidative Stress and Neurodegeneration in the CNS 
1.2.1. Reactive species in the brain 
The human brain accounts for only 2% of the body weight but it processes 20% 
of basal O2 consumption [81]. During aerobic energy metabolism, electrons are 
transported via the electron carriers in the mitochondria to generate ATP and 
oxygen acts a final acceptor of electrons and gets reduced to form water [82]. A 
substantial concentration of oxygen gets partially reduced to form reactive 
oxygen species (ROS). Over 90% of ROS is produced in the mitochondria [83], 
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with superoxide (O2−) making up a substantial fraction. An important enzymatic 
source of superoxide is nicotinamide adenine dinucleotide phosphate oxidase 
(NADPH oxidase) which catalyzes a one electron reduction of molecular oxygen 
to form ·O−2 [84]. 
O2− may undergo Haber–Weiss reaction (.O2− +H2O2  .HO +O2 + HO−), 
generating more toxic radicals. Iron salts and metal ions present at low levels in 
biological systems, serve as catalysts for this pathway [85]. Trace elements, iron, 
aluminum, mercury, and copper are capable of stimulating free radical 
generation. Iron is an important source of reactive species through its 
participation in the Fenton reaction. Studies have demonstrated that H2O2 can 
oxidize Fe2+ to produce hydroxide (OH−) and the highly reactive hydroxyl radical 
(OH•), and this constitutes the Fenton reaction [86]. The highly toxic hydroxyl 
radical is very reactive with lipids [87].  
Additional reactive species derived from nitrogen (Reactive nitrogen species or 
RNS) include nitric oxide (NO) [88], peroxynitrite (ONOO−), nitrogen dioxide 
(NO2), and nitroxyl (HNO). These reactive species are all capable of causing 
oxidative modifications of lipids, proteins, or DNA. 
1.2.2. Oxidative stress in the brain 
Under physiological conditions, RNOS generation and the endogenous 
antioxidant systems are well-balanced. However, if the level of RNOS increases 
or the level of antioxidants decreases, this balance will be disturbed leading to 
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oxidative stress in the CNS. Helmet Sies defined oxidative stress as “a 
disturbance in the pro-oxidant - antioxidant balance in favor of the former” [89]. 
Subsequent research has shed some light on redox signaling and its 
consequence on the oxidative status of cells and this has redefined oxidative 
stress as “a disruption of redox signaling and control.” (reviewed in [90]). 
Oxidative reactions are key players in aging and major disease processes, 
including but not limited to cancer, cardiovascular and pulmonary diseases, 
diabetes and neurodegeneration [91-94]. The oxidation of biomolecules such as 
DNA and proteins and the peroxidation of lipids can initiate deleterious processes 
in a variety of acute and chronic neurological disorders/diseases [95-102].  
Lipid peroxidation is the oxidation of lipids that is a crucial step in the 
pathogenesis of several diseases. Several lipid molecules containing double 
bond(s) can be oxidized under appropriate conditions [103]. The mechanisms 
inducing lipid peroxidation are complex. Polyunsaturated fatty acid is known to be 
rich in the membranes of neurons. Lipid peroxidation is the result of attack by 
radicals on the double bond of unsaturated fatty acids, such as arachidonic acid, 
to give rise to highly reactive lipid peroxy radicals that initiate a chain reaction of 
further attacks on other unsaturated fatty acids. Lipid peroxidation is a self-
propelling chain-reaction and the initial oxidation of a few molecules can result in 
magnified tissue damage. Primary peroxidation products of fatty acid oxidation 
are hydroperoxides in which double bond(s) may have moved or/and changed 
configuration. These products may be converted into secondary peroxidation 
 
  
9 
 
products [104]. Lipid peroxides and lipid-derived aldehyde adduct proteins are 
players in the cascade of neurodegeneration [105]. Two main products of the 
peroxidation reaction are: malondialdehyde (MDA) and, in particular, 4-hydroxy-
2-nonenal (4-HNE) that are also used as biomarkers of oxidative stress [106]. 
Proteins are another target of reactive species. Protein oxidation has also been 
studied in disorders and diseases involving oxidative stress. Covalent 
modification of protein takes place in the oxidation reaction and is induced either 
by the direct reactions with reactive species or indirectly by the secondary by-
products of oxidative stress [107]. The amino acids cysteine and methionine are 
most vulnerable to oxidative changes due to the sulfur groups. Protein carbonyl 
content (PCC) is the most widely used marker of protein oxidation in cells [108]. 
Finally, oxidation of DNA is another consequence of release or imbalance of 
reactive species in the cell. Irrespective of their origin, RNOS may interact with 
DNA, leading to modification of the bases. Pyrimidine radicals can occur as a 
result of oxidative damage yielding numerous products by several mechanisms 
[109]. Hydroxyl radical reacts with DNA by addition to double bonds of DNA 
bases and by abstraction of an H atom from the methyl group of thymine and 
moieties of ribose sugar in the backbone [110]. Hydroxyl radical can also induce 
the formation of DNA-protein cross-links. Thymine-tyrosine cross-link is the 
product from the formation of a covalent bond between the methyl group of the 
thymine and the third carbon of the tyrosine ring [110]. Guanine, a purine, can be 
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attacked by hydroxyl radicals as well as singlet oxygen leading to the formation 
of 8-oxo-7,8-dihydroguanine, a typical marker of DNA oxidation [111]. 
Neuronal cell death is a complex process and involves multiple mechanisms. 
Oxidative stress may not be the cause of neuronal cell death, per se, but 
contribute to the cascade eventually leading to cell death [76]. RNOS are 
secondary to disorders and diseases in the CNS and can damage neurons and 
promote the release of excitatory amino acids, generating a harmful chain of 
events [112]. They can also initiate self-propelling reactions leading to the 
formation of more complex reactive species, the presence of which may be 
detrimental to the cells.  
1.2.3. Antioxidants in the brain 
The brain has a wide spectrum of antioxidants which may act enzymatically 
(superoxide dismutase, catalase, glutathione peroxidase) or non-enzymatically 
(Vitamin E, Vitamin C and glutathione) to detoxify RNOS [113, 114]. A short 
review of each follows: 
Vitamin C or Ascorbic Acid: Ascorbic acid is a potent water soluble dietary 
antioxidant with the ability of neutralizing a spectrum of reactive oxygen species 
such as hydroxyl, alkoxyl, peroxyl, superoxide anion, hydroperoxyl radicals and 
reactive nitrogen radicals such as nitrogen dioxide, nitroxide, peroxynitrite at very 
low concentrations [115]. Vitamin C has been shown to interact with free, 
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catalytically active metal ions producing hydroxyl and alkoxyl in vitro. It is 
controversial whether this mechanism occurs in vivo [115]. 
Vitamin E: Unlike vitamin C which is water soluble, Vitamin E is a fat soluble 
dietary antioxidant [116]. It is a potent scavenger of peroxyl radical and controls 
the propagation of free radical damage in biological membranes [117]. More 
information can be found in this comprehensive review [118].  
Super oxide dismutase (SOD): SOD catalyzes the conversion of two moles of 
·O2− to H2O2, which is itself converted to water by catalase and glutathione 
peroxidase. There are four known SODs. Copper (Cu) and zinc (Zn) SODs 
(CuZn) are present in the cytosol and manganese (Mn) SOD is mitochondrial. An 
extracellular SOD (EC SOD) has also been identified [84]. 
Catalase: Catalases are ubiquitous enzymes that prevent cell oxidative damage 
by degrading hydrogen peroxide to water and oxygen (2H2O2 → 2 H2O + O2) with 
high efficiency [119]. 
Glutathione: Of particular interest for this thesis is glutathione (GSH). GSH is not 
only an antioxidant but is also required for the maintenance of cellular health and 
proliferation [120]. The details of glutathione metabolism, reactions, transport and 
import are discussed in detail in the next section.  
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1.3. Glutathione  
1.3.1 Glutathione synthesis, function transport and import. 
GSH Synthesis: GSH is a tripeptide thiol comprised of cysteine, glutamate and 
glycine (γ-L-glutamyl-L- cysteinylglycine). It is believed to be the most abundant 
antioxidant in the central nervous system (CNS) [121, 122]. The cellular thiol is 
present in concentrations up to 12 mM in mammalian cells [121]. GSH is a major 
redox regulator in the cells [123]. GSH synthesis takes place via a sequential 
two-step enzymatic reaction [113, 124]. 
 
Figure 1: Glutathione synthesis 
(Adapted from http://www.vitamor.com/immunopro/glutathion.htm) 
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GSH maintains the thiol redox potential in cells by keeping sulfhydryl groups of 
cytosolic proteins in the reduced form. It has important functions as an 
antioxidant, a detoxification reagent for xenobiotics and a storage and transport 
form of the amino acid cysteine [121, 125]. GSH can act either as a non-
enzymatic scavenger or a co-factor (an electron donor) for the antioxidant 
enzyme glutathione peroxidase (GPx) (reviewed in [96, 126]). GSH reacts 
directly with radicals in non-enzymatic reactions and is the electron donor in the 
reduction of peroxides catalyzed by glutathione peroxidase. GPx is a 
selenocysteine-containing enzymes and exists as a group of isozymes. A 
selenium- independent GPx has been identified [127-129]. Glutathione 
peroxidase 1 (GPx1) is the most abundant version and it has been found to 
localize primarily in neuroglial cells, in which the peroxidase activity is tenfold 
higher than in neurons [130].  
Upon oxidation, GSH is converted to glutathione disulfide (GSSG). Regeneration 
of GSH from GSSG takes places in a reaction catalyzed by the enzyme 
glutathione reductase (GR) (reviewed in [96]). GR uses NADPH for the transfer 
of a reduction equivalent. 
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Figure 2. Glutathione reactions (Figure adapted from [131]). 
GSH S-transferases catalyze the conjugation of GSH to a variety of toxic reaction 
products formed by the ROS-dependent peroxidation of intracellular molecules 
[132]. 
Transport of GSH: GSH is synthesized intracellularly but there is a requirement 
for glutathione not only in the cytoplasm, but in the extracellular milieu. The 
transport of glutathione to the different organelles as well as across the cell 
membrane has been biochemically demonstrated by several studies; however, 
the molecular identity of the transporters has not been completely deciphered 
[133]. GSH homeostasis across the cell membrane requires glutathione 
transport. Studies from the 1970s proposed the presence of GSH specific 
carriers that mediate efflux into plasma and other extracellular fluids [134]; 
however, the direct uptake of GSH molecule into the cells is a subject of 
debate[135].  
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The multi drug resistance protein (Mrp) family of transporters, which is a sub-
class of the ATP-Binding Cassette (ABC) transporter superfamily, have been 
found to transport GSH across the membranes [136]. The Mrp proteins mediate 
not only GSH export, but also export of its oxidized derivatives such as GSSG, S-
nitrosoglutathione (GS-NO), and glutathione–metal complexes, as well as other 
glutathione S-conjugates [137]. The Mrp family has five proteins (Mrp1-5). Mrp1 
is a transporter that is present in all tissues. Several mechanisms have been 
proposed with respect to transport of GSH: a) GSH itself is a substrate for the 
Mrp transporters, b) GSH is co-transported with another substrate and c) GSH 
transport is stimulated by some compounds which are not transported 
themselves (reviewed in [137]). The Km for GSSG and GSH transport through 
mammalian Mrp1 are 100 µM and 1-10 mM respectively [133]. 
Uptake of GSH: The uptake of intact GSH into mammalian cells has been much 
debated [138]. Biochemical experiments have shown the presence of Na+-
dependent and Na+-independent glutathione transport systems in brain cells 
[139]. Studies have also shown the import of products of GSH degradation. 
Degradation of GSH by γ-GT is followed by uptake of the constituent products 
and re-synthesis of GSH. 
As mentioned, GSH is an important antioxidant/thiol reagent for maintenance of 
cellular homeostasis for all cell types. However, as the focus of this thesis is on 
astrocyte and neurons, I will restrict comments to these cell types when 
describing its role in the CNS.  
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1.3.2 Glutathione in the CNS 
The amount of GSx (GSH+GSSG) in neurons is almost exclusively GSH with just 
2.5% being GSSG and application of cysteine in the absence or the presence of 
glycine and/or glutamine has resulted in a doubling of the neuronal glutathione 
content [140]. Astrocytes, on the other hand, prefer to use cystine instead of 
cysteine for GSH synthesis and are very efficient in transporting the GSH to the 
extracellular space [141]. The GSH released from astrocytes is partially used as 
substrate of the ectoenzyme γ-Glutamyl transpeptidase (γGT) [142]. The 
dipeptides CysGly (product of the reaction catalyzed by γGT) and γGluCys can 
serve as precursors for glutathione synthesis in the neurons [140]. 
In general, neuronal GSH levels are lower than astrocytic GSH [124] rendering 
them more susceptible to oxidative injury. It was found that neurons co-cultured 
with astrocytes have higher levels of glutathione than neurons cultured alone, 
suggesting that astrocytes enhance the neuron antioxidant levels [143]. 
Astrocytes export a substantial amount of their GSH (10%/hr) into the 
extracellular space via the Mrp1 transporter [144]. Evidence suggests that it is 
broken down into dipeptides CysGly and γGluCys, which can serve as 
precursors for glutathione synthesis in the neurons. Cysteine is a rate-limiting 
substrate for GSH synthesis and it has been shown to be derived from astrocytes 
for the neuronal GSH homeostasis [145, 146]. 
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1.3.3 IL-1β and GSH Synthesis in the CNS 
System xc- functions in a Na+-independent and Cl- - dependent manner with 1:1 
exchange of extracellular cystine for intracellular glutamate [147] and is central to 
the production of glutathione in all cells [148] and astrocytes are no exception. 
Astrocytic regulation of system xc- has been studied extensively by the laboratory 
and previous studies have found that IL-1β enhances astrocytic system xc- 
expression and functional activity [67, 149]. Pertinent to this thesis, this increase 
has been shown to result in an enhancement of astrocytic GSH synthesis and its 
subsequent export [1]. Additionally, our laboratory demonstrated that IL-1β 
protects the astrocyte from oxidative stress through a GSH-dependent 
mechanism. Whether a similar effect is found in neurons or whether astrocyte 
GSH production can confer protection to neurons in co-culture is the subject of 
this thesis. 
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1.4. Specific Aim 
To study the neuroprotective potential of exogenous IL-1β against 
oxidative stress-mediated damage in vitro. 
The hypothesis that IL-1β-induced enhancement of astrocytic GSH protects 
neurons against oxidative stress was tested. Studies suggest that astrocytic 
enhancement of GSH is protective against oxidative damage in a cell-
autonomous fashion. There is also strong evidence by others that astrocytes 
protect neurons (i.e., non- cell autonomously) from oxidative stress induced 
toxicity via GSH coupling. To test whether IL-1β can protect neurons either in a 
cell autonomous or non-cell autonomous manner, mixed cortical cell cultures 
containing neurons and astrocytes as well as near pure neuronal cultures were 
employed. Specifically, we aimed to decipher whether IL-1β can protect neurons 
in culture, much the way our laboratory has determined it protects astrocytes. 
Additionally, whether oxidative stress-induced neuronal injury is observed in 
chimeric cultures consisting of neurons derived from wild-type mice plated on top 
of astrocytes derived from IL-1R1 null animals (these animals lack the ability to 
signal through IL-1β), which fail to show an increase in GSH synthesis and 
release following IL-1β exposure, was also assessed. 
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Chapter 2. Materials and Methods 
2.1 Experimental Animals 
This study was conducted in accordance with the National Institute of Health 
guidelines for the use of experimental animals and has been approved by the 
Institutional Animal Care and Use Committee of Syracuse University. CD-1 mice 
were obtained from Charles River Laboratories (Wilmington, MA) and were used 
in all experiments unless indicated otherwise. The il1r1 null mutant animals 
(Strain: B6.129S7-IL1r1tm1lmx/J; JAX stock # 003245) [56] were purchased from 
JAX Labs (Bar Harbor, ME) and bred homozygously in parallel with animals from 
the background strain (JAX stock # 000664). Offspring from the C57BL/6J were 
used as wildtype controls (C57BL/6). 
2.2. Cell Culture 
Cell culture media and experimental buffer compositions were as follows: Media 
stock (MS): L-glutamine-free modified Eagle’s medium (Earl’s salt; MediaTech) 
supplemented with L-glutamine, glucose, and sodium bicarbonate to a final 
concentration of 2.0, 25.7, and 28.2 mM, respectively; Astrocyte plating medium: 
MS containing 10% fetal bovine serum (FBS; Hyclone) and 10% calf serum (CS; 
Hyclone), 10 ng/mL epidermal growth factor (Invitrogen), 50 IU penicillin, and 50 
µg/mL streptomycin (Gibco); Astrocyte maintenance medium: MS containing 
10% CS and 50 IU penicillin/ 50 µg/mL streptomycin. Neuronal plating medium: 
MS containing 5% bovine growth serum (BGS; Hyclone) and 5% CS (Hyclone), 
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50 IU penicillin, and 50 µg/mL streptomycin (Gibco); Neuronal culture medium: 
Neurobasal medium (NB) containing 1x B27 supplement (Invitrogen), 2 mM L-
glutamine, 50 IU penicillin and 50 µg/mL streptomycin. 
Primary astrocytes were cultured from pooled cortices of postnatal CD-1 pups (1-
3 days; Charles River) as described in detail previously [150]. IL-1R1 wild-type 
and null mutant astrocytes were cultured from cerebral cortices of pups derived 
from IL-1R1 null homozygous breeding pairs. The remainder of brain tissue was 
used to confirm the genotype following dissection of the cerebral cortices, as 
described [http://jaxmice.jax.org/strain/003245.html].  
In brief, following an aseptic dissection, cerebral cortices were placed in 0.025% 
trypsin diluted in Hank’s balanced salt solution (Mediatek) and incubated for 15 
min at 37◦C. Dissociated cells were pelleted via centrifugation (3 min, 760 g), 
medium decanted and cells resuspended in astrocyte plating medium and plated 
at the equivalent of 2 hemispheres per 10 mL in 24-well plates (Falcon, 
Primaria). Upon confluence, monolayers of astrocytes were treated with 8 µM β-
D-cytosine arabinofuranoside (AraC) once for 6-7 days to prevent microglial cell 
growth. Following this, astrocytes were fed every 7-8 days with astrocyte 
maintenance medium. Astrocytic cultures were used between 21-30 days in vitro. 
To remove any residual microglia before use in experiments, astrocyte 
monolayers were incubated with 50 mM of leucine methyl ester (LME) for 25-30 
min one day prior to experimentation. Since C57BL/6J are more sensitive to 
LME, they were incubated with 50 mM LME for 20 minutes only.  
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Primary near-pure neuronal cultures were derived from the cortices of embryonic 
day 15 CD-1 mice, essentially as described above for astrocytes except that they 
were plated at a density of 1 million cells/mL in polyethyleneimine-coated plates 
in the neuronal plating medium. Four hours later, medium was exchanged and 
cells were placed in neuronal culture medium. After two days, neurons were 
treated with 1 µM of AraC once for 2 days to prevent glial cell growth. Medium 
was partially replenished two days later, at 4 days in vitro by exchanging 250 µL 
of medium with neuronal culture medium made using 1xB27 supplement devoid 
of antioxidants (B27 minus AO; Invitrogen) to remove existing antioxidants in the 
medium. Pure neuronal cultures were used at 6-7 days in vitro. 
Mixed cortical cell cultures consisting primarily of neurons and astrocytes were 
prepared by plating dissociated cortical cells (0.75-0.8 million cells/mL) from 
embryonic day 15 CD-1 mouse fetuses on a confluent layer of astrocytes in 
neuronal plating medium. The medium was partially replaced after 5 and 9 days 
in vitro and treated with 8 µM of AraC once at 7 days in vitro. Two days prior to 
experimentation, mixed cortical cell cultures were placed into media stock. 
Experiments were performed at 14 days in vitro. All cultures were kept at 37°C in 
a humidified 6% CO2-containing incubator. 
2.3. IL-1β Treatment 
Cells were treated with various concentrations of recombinant murine IL-1β (R&D 
Systems) for various times in an incubation buffer of MS for astrocytes and mixed 
cultures and NB for neurons both supplemented with the vehicle, 0.1% fatty-acid 
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free BSA (Sigma). Cells were then returned to a humidified 37˚C normoxic (21% 
O2) incubator containing 6% CO2. 
2.4. Measurement of GSH 
Total glutathione (GSH + GSSG) concentrations were measured both 
intracellularly ([GSH]i) and extracellularly ([GSH]e) using the GSH-Glo glutathione 
assay (Promega, Madison, WI) per manufacturer’s instruction. Media was 
collected for analysis of [GSH]e and GSH Glo reaction buffer was added to the 
cells for lysis and analysis of [GSH]i. Samples were diluted using the reagent to 
keep relative light units within the dynamic range of the standards. To determine 
total GSH (reduced) levels, oxidized glutathione disulfide (GSSG) within the 
samples was converted to reduced GSH with the reducing agent TCEP-HCl (final 
concentration = 1 mM; 10 min; 25°C; Thermo Scientific; Waltham, MA). 
Luciferase activity was quantified using a Synergy 2 microplate reader (BioTek, 
Winooski, VT). Total intracellular or extracellular GSH were normalized to 
standards prepared in GSH-Glo reagent and MS containing L-glutamine and 
0.1% fatty acid free BSA, respectively. Intracellular GSH was normalized to 
cellular protein quantified using BCA Assay Kit (Thermo Scientific) as per the 
manufacturer’s instructions. GSH standards were linear over the range of 0 to 5 
µM. 
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2.5. Drug Exposure 
Tert-butyl Hydroperoxide (t-BOOH) Treatment: t-BOOH is a direct-acting 
organic peroxide used to induce oxidative stress, the clearance of radicals 
generated by which is GSH-dependent. A stock solution of t-BOOH (1.5 M in 
H2O; Acros Organics) was made and stored at 4°C. t-BOOH was added to the 
cultures (final concentration: 0.1–4 mM) in treatment media (MS for astrocytes 
and mixed cultures and NB for neurons). Experiments were terminated 2.5 to 3.5 
h later and tissue culture supernatant was removed for the measurement of 
lactate dehydrogenase (LDH) activity as an assessment of cell death. Following 
the harvest of samples for LDH assay, MTT assay was carried out by the 
addition of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to 
assess for cell survival. Minimum incubation for MTT assay: 2 h. 
MK-571: MK-571 is a potent inhibitor of the Mrp1 transporter, a transporter used 
by astrocytes to export GSH. A stock solution of MK-571 (25 mM in H2O; Enzo 
Life Sciences) was made and stored at -20°C. MK-571 was added to the cultures 
(final concentration: 50-70 µM) in treatment media (MS for astrocytes and mixed 
cultures). After 1.5 h of incubation, wells were treated with IL-1β for 24 h followed 
by challenge with t-BOOH as described in each figure legend. Experiments were 
terminated 2.5 to 3.5 h later by addition of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to assess for cell survival. 
Glutathione Ethyl Ester (GEE) addition: GEE is a membrane permeable 
derivative of GSH that is used to supplement GSH supply within cells. A 0.5 M 
 
  
24 
 
stock of GEE (Sigma) was made freshly for each experiment in NB. GEE was 
added to neuronal cultures at final concentration of 0.5 to 3 mM. 
2.6. Measurement of Cell Death and Viability 
Cell Death: Cell death was quantitatively determined by spectrophotometric 
measurement of lactate dehydrogenase (LDH) as described previously [151]. In 
short, LDH activity was determined by measuring the pyruvate-dependent rate of 
oxidation of NADH. To do so, 40 µL tissue culture supernatant were added to 
potassium phosphate buffer (100 mM, pH 7.4, 150 µL). Then, NADH (0.4 mM, 
125 µL), followed by pyruvate (23 mM, 50 µL) was added for a total reaction 
volume of 375 µL. Immediately following the addition of pyruvate, the loss of 
absorbance at 340 nm - an index of NADH oxidation - was recorded every 34 s 
for a period of 4 min using a microplate reader SpectraMax M2 (Molecular 
Devices). A standard curve was constructed using Level II Control Serum (Pointe 
Scientific Inc.), from which LDH concentration in the experimental medium was 
calculated via linear regression. Astrocyte and mixed culture injury was quantified 
as a percentage of total astrocytic LDH activity (defined as 100%) determined by 
exposure of parallel cultures to 20 µM Calphostin C for 20-24 h [152].  
Cell Viability: Cell viability was quantified via colorimetric analysis of MTT 
(Sigma) reduction as previously described [153]. Following treatment, MTT was 
added to the cultures (final concentration = 300 µg/mL) for at least 3 h at 37°C, 
after which the solution was carefully aspirated, and the resulting crystals 
solubilized in acidified isopropanol (90% isopropanol; 10% 1 N HCl; 400 µL/well). 
 
  
25 
 
200 µL was transferred to a 96-well plate and absorbance at 540 nm was 
measured against a 690 nm background subtraction (SpectraMax M2, Molecular 
Devices). Percent viable astrocytes was quantified by normalization of 
experimental MTT absorbance values to values obtained from untreated control 
cells (i.e., highest absorbance = 100%) as well as cells treated with 1.5 mM t-
BOOH, 20 µM Calphostin C or 300 µM NMDA, which result in complete loss of 
viability (defined as 0%). 
2.7. Propidium Iodide Staining 
In some mixed culture experiments, cell death was additionally assessed via 
propidium iodide (PI; Molecular Probes) staining [154]. Live cells exclude PI. In 
short, PI (10µg/mL) was added to culture wells for 10 min, after which PI was 
removed by gentle washing with PBS (3 x 750 µL) and imaged. Fluorescent 
photos were acquired by a DP73 digital color camera (Digital Video Camera Co.) 
mounted on an Olympus IX50 inverted microscope outfitted with epifluorescence 
controlled by CellSens Standard (Olympus) software. Brightness and contrast 
were standardized for each picture. 
2.8. Statistical Analysis  
All statistical analyses were performed using GraphPad Prism Version 6.0 as 
described. Percentage data were transformed (arcsin square root) before 
analysis because it is non-normally distributed. In all experiments, data are 
expressed as the mean + SEM. Significance was assessed at p < 0.05. 
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Chapter 3. Results 
The goal of the following experiments was to test the protective potential of IL-1β 
against t-BOOH injury employing astrocytes, neurons and co-cultures of the two. 
The results have been accordingly divided into 3.1 for astrocytes, 3.2 for neurons 
and 3.3 for mixed culture and 3.4 for neurons + GEE. 
3.1. Astrocytes 
In confirmation of previous findings in the laboratory [1]: 1) treatment of enriched 
cortical astrocytes with IL-1β (5 ng/ mL) for 48 h resulted in an increase in the 
extracellular GSH that accumulated in the supernatant, while the intracellular 
levels remained unchanged (Figure 3); 2) t-BOOH toxicity to astrocytes was 
abolished by IL-1β pretreatment (Figure 4); 3) astrocytic cultures derived from 
il1r1 null mutant mice, that is mice lacking the IL-1β signaling receptor, show no 
increase in extracellular GSH following stimulation with IL-1β (Figure 5A), nor do 
these cells enjoy any protection when treated with t-BOOH, as compared with 
astrocytes derived from wild-type control mice (Figure 5B).  
Interestingly, the basal extracellular GSH levels as well as the IL-1β-mediated 
enhancement were concentration-dependently blocked by concomitant treatment 
of astrocytes with MK-571 (50–70 µM), suggesting that release occurred via 
Mrp1, as has been reported previously [155] (Figure 6A). Despite this, the toxicity 
of t-BOOH and the protection afforded by IL-1β pre-treatment was not 
appreciably affected by MK-571 (Figure 6B).  
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3.2. Neurons 
We next set out to determine whether IL-1β pre-treatment could affect neuronal 
GSH levels. Unlike in astrocytes, treatment of enriched cortical neurons with 5 
ng/ mL of IL-1β for 48 h did not cause any change in the levels of intracellular or 
extracellular GSH (Figure 7), begging the question as to whether it would protect 
neurons in isolation against an oxidant stressor. In order to test this, we first 
needed to find a t-BOOH concentration that would facilitate neuronal injury in a 
similar exposure time frame as astrocytes. As demonstrated in Figure 8, lower 
concentrations of t-BOOH effectively resulted in neuronal cell death, but they 
required longer exposure. Concentrations of t-BOOH between 1-4 mM resulted in 
57.5% ± 3.03 cell death in a time frame similar to that used in astrocyte 
experiments (3.5 h) and as such these concentrations were chosen for 
subsequent experiments with neurons. Exposure of neurons to increasing 
concentrations of t-BOOH (1, 2 and 4 mM) resulted a concentration-dependent 
toxicity that was unabated by treatment with IL-1β (5 ng/ mL; 48 h) (Figure 9). To 
ensure that the lack of protection was not a result of sub-optimal IL-1β 
concentrations, neurons were treated with increasing concentrations of IL-1β (5-
20 ng/ mL; 48 h) and then challenged with 2 mM t-BOOH. At every concentration 
tested, IL-1β failed to rescue neurons from t-BOOH toxicity (Figure 10). Given the 
fact that IL-1β treatment also failed to raise the levels of neuronal GSH level, 
these results might not be unexpected.  
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3.3. Mixed culture 
Astrocytes and neurons have been shown to function together and have 
beneficial interactions in the CNS. Since the data demonstrated that astrocytes 
responded to IL-1β by releasing GSH, we next investigated if this astrocytic 
response could be neuroprotective in a co-culture of astrocytes and neurons. As 
both neurons and astrocytes have functional IL-1R1 receptors, we chose a 
higher concentration of IL-1β (10 ng/ mL) for treating the cells to ensure that 
astrocytes signaling would be optimal (S Hewett Lab, unpublished observations). 
Treatment of mixed culture with IL-1β (10 ng/ mL; 48 h) resulted in a significant 
increase in the levels of extracellular GSH (Figure 11). Additionally, cells in mixed 
culture receiving the IL-1β pretreatment were protected against t-BOOH toxicity. 
Specifically, t-BOOH exposure reduced the cell viability by approximately 55% ± 
4.6 for 1.5 mM t-BOOH and 60% ± 4.6 for 2 mM t-BOOH, while cell viability in the 
IL-1β-treated group was only reduced by 20% ± 4.4 for 1.5 mM t-BOOH and 32% 
± 6.3 for 2 mM t-BOOH (Figure 12). Using propidium idodide (PI) to stain dead 
and dying cells, we found that both neurons and astrocytes were vulnerable to t-
BOOH toxicity and that both cell types were protected by IL-1β pretreatment 
(Figure 13).  
To investigate whether the protective effect of IL-1β was dependent on astrocyte 
signaling, we generated chimeric cultures in which either il1r1 +/+ or -/- 
astrocytes were co-cultured with wild-type neurons. Cultures containing il1r1 -/- 
did not respond to IL-1β treatment (10 ng/ mL, 48 h) with an increase in GSH 
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synthesis and release as compared to those containing il1r1 +/+ (Figure 14). 
Additionally, chimeric cultures containing il1r1 -/- were not protected against t-
BOOH toxicity (1.5 mM t-BOOH; 2 h) by prior IL-1β treatment (10 ng/ mL, 48 h) 
whereas those containing il1r1 +/+ astrocytes were rescued (Figure 15).  
Finally to determine whether extracellular GSH release was necessary for the 
protective effect of IL-1β in the mixed culture system, release of GSH was 
abrogated by treatment with the Mrp1 blocker, MK-571 (50–70 µM) (Figure 16A). 
Interestingly, the protective effect of IL-1β was significantly attenuated when GSH 
release was reduced (Figure 16B). These findings point towards the antioxidant 
aspect of the intricate cross-talk between astrocytes and neurons in the brain. 
Unfortunately, we did not assess the potential cell-type specificity of the 
response.  
3.4. Neurons + GEE  
To determine whether supplementing neurons in near pure culture with external 
glutathione could substitute for the presence of astrocytes, we provided neurons 
in culture with glutathione ethyl ester (GEE, 0.5-3 mM) (Figure 17A), then 
challenged them with 2 mM t-BOOH for 3 h (Figure 17B). The intracellular GSH 
increased significantly upon treatment with 3 mM GEE; however, GEE treatment 
did not rescue neurons from t-BOOH toxicity and in fact it was toxic on its own 
(Figure 17B). Thus, we can draw no conclusions regarding the role of GSH 
supplementation using this paradigm.  
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Figure 3: IL-1β pre-treatment increases the GSH status of astrocytes. 
Astrocytes cultured from CD-1 mice (400 µL/well, 0.16 ± 0.007 mg 
protein/well) were washed twice with treatment media and incubated with 
IL-1β (5 ng/mL) or vehicle for 48 h, after which total intracellular (n = 6 
from two separate dissections) and extracellular (n = 12 from 4 separate 
dissections) GSH levels were measured. Data are expressed as mean + 
SEM. An asterisk (*) denotes a significant between-group difference 
(comparisons between vehicle and IL-1β treated cultures) as assessed by 
Mann-Whitney U test (p = 0.0083).  
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Figure 4: IL-1β pre-treatment protects pure astrocytes against t-
BOOH-mediated cell death. Astrocytes cultured from CD-1 mice were 
washed twice with treatment media and incubated with IL-1β (5 ng/mL) or 
vehicle for 48 h after which they were treated with the t-BOOH 
concentrations indicated for 3.25 h. Cell viability was determined via the 
measurement of mitochondrial succinate dehydrogenase using the MTT 
assay. Data are expressed as % astrocyte viability (mean + SEM) 
normalized to MTT values found in the untreated group; n = 9-10 from two 
separate dissections. An asterisk (*) denotes significant between-group 
differences (+ and - IL-1β at each t-BOOH concentration) as assessed by 
two-way ANOVA followed by Bonferroni’s test for multiple comparisons (p 
≤ 0.0002). 
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Figure 5: Increase in extracellular GSH and protection against t-
BOOH-mediated cell death in astrocytes is purely due to IL-1β 
signaling through IL-1R1. (A) Astrocytes (n = 12 from two separate 
dissections) from il1r1 +/+ or -/- mice were washed twice with treatment 
media and incubated with IL-1β (5 ng/mL) or vehicle for 48 h after which 
total supernatant GSH levels were measured. (B) Astrocytes from the 
same dissections (n = 13-15) were treated with 0.7 mM t-BOOH for 2.25 h, 
after which experiments were terminated by addition of MTT to assess for 
cell survival. Data are expressed as mean + SEM. For B, viability data are 
expressed as % astrocyte viability normalized to MTT values found in the 
untreated group (= 100%). An asterisk (*) denotes significant between-
group differences (+ and - IL-1β in the same genotype) as assessed by 
two-way ANOVA followed by Bonferroni’s test for multiple comparisons (p 
= 0.0007 for A and p < 0.0001 for B). 
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Figure 6: Attenuation of astrocytic GSH extrusion does not affect the 
cellular viability upon t-BOOH challenge. Astrocyte cultures derived 
from CD-1 mice were washed twice with treatment media and incubated 
with different concentrations of MK-571 as indicated for 1.5 h, after which 
the wells were treated with IL-1β (5 ng/mL) or vehicle for an additional 24 
h. Thereafter, total supernatant GSH levels were measured (A) 
Subsequently, wells were challenged with 1.5 mM t-BOOH for 2.45 h after 
which cell viability was determined via the MTT assay (n = 8 from four 
separate dissections). (B). Data are expressed as mean + SEM. For B, 
viability data are expressed as % astrocyte viability normalized to MTT 
values found in the untreated group (= 100%) (n = 6-8 from four separate 
dissections). An asterisk (*) denotes significant between-group difference 
(+ and – IL-1β with or without MK-571) and a pound (#) denotes significant 
within-group difference (+ and – IL-1β treated) as assessed by two-way 
ANOVA followed by Bonferroni’s test for multiple comparisons. (p = ≤ 
0.035 for * and p ≤ 0.0054 for #). 
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Figure 7: IL-1β pre-treatment does not change the GSH status of 
neurons. Neurons cultured from CD-1 mice were washed twice with 
treatment media and incubated with IL-1β (5 ng/mL) or vehicle for 48 h, 
after which total intracellular and supernatant GSH levels were measured 
(well volume = 400 µL, 0.36 ± 0.024 mg protein/ well). Data are expressed 
as mean + SEM. No significant difference was observed between groups 
(vehicle vs. IL-1β treated cultures) as assessed by two-way ANOVA (n = 9 
from three separate dissections).  
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Figure 8: t-BOOH causes cell death in a concentration-dependent 
manner in neurons. Neurons cultured from CD-1 mice were washed 
twice with treatment media and incubated for (A) 6.5 h (n = 8 from two 
independent experiments) (B) 7 h (n = 8-9 from three independent 
experiments) or (C) 3.5 h (n = 4-8 from two independent experiments) with 
the t-BOOH concentrations as indicated. Neuronal viability was 
determined by the MTT assay. Data are expressed as % mean neuronal 
viability + SEM normalized to non-treated group (= 100%). Asterisks (*) 
denote significant differences between untreated cultures (0 mM) and t-
BOOH treated cultures as assessed by one-way ANOVA followed by 
Dunnett’s test for multiple comparisons. p ≤ 0.0017 for A, p < 0.0001 for B 
and p < 0.0001 for C.  
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Figure 9: IL-1β pre-treatment does not protect neurons against t-
BOOH-toxicity. Neurons cultured from CD-1 mice were washed twice 
with treatment media and incubated with IL-1β (5 ng/mL) or vehicle for 48 
h. Next cells were treated with the t-BOOH concentrations indicated (1.25 
to 4.5 h) and cell viability was determined using the MTT Assay. Data are 
expressed as % neuronal cell viability (mean + SEM) normalized to MTT 
values of the untreated group (= 100%). No significant between-group 
differences (+ and - IL-1β at each t-BOOH concentration) were observed 
as assessed by two-way ANOVA followed by Bonferroni’s test for multiple 
comparisons (n = 6-9 from two separate dissections). 
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Figure 10: Increasing the concentrations of IL-1β pre-treatment does 
not protect pure neurons against t-BOOH-mediated cell death. 
Neurons cultured from CD-1 mice were washed twice with treatment 
media and incubated with different concentrations of IL-1β or vehicle as 
indicated in the figure. 48 h later, cultures were treated with 2 mM t-BOOH 
for 3.5-4 h a after which the experiment was terminated by addition of 
MTT to assess for cell survival. Because there was no significant 
difference in cell viability between each respective control (i.e., vehicle-
treated group for each IL-1β concentration), values were pooled and are 
represented as a single group for ease of presentation. Data are 
expressed as % mean neuron viability + SEM, normalized to MTT values 
of the untreated control cultures (= 100%). No significant between-group 
difference was observed as assessed by two-way ANOVA followed by 
Bonferroni’s test for multiple comparisons. (n = 7-8 from two separate 
dissections). 
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Figure 11: IL-1β pre-treatment increases the GSH release from mixed 
cultures. Mixed cortical cultures from CD-1 mice were washed twice with 
treatment media and incubated with IL-1β (10 ng/mL) or vehicle for 48 h 
after which total supernatant GSH levels were measured. Data are 
expressed as mean μM/well + SEM. An asterisk (*) denotes significant 
difference as assessed by Student’s t-test (p = 0.0006) (n = 22-24 from 
five separate dissections). 
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Figure 12: IL-1β pre-treatment protects mixed cultures against t-
BOOH toxicity. Mixed cortical cell cultures from CD-1 mice were washed 
twice with treatment media and incubated with IL-1β (10 ng/mL) or vehicle 
for 48 h. Next, cultures were treated with t-BOOH at concentrations 
indicated for 2.75-3.25 h. The experiment was then terminated by addition 
of MTT to assess for cell survival. Data are expressed as % mean cell 
survival + SEM normalized to MTT values of the non-treated control 
cultures (= 100%). An asterisk (*) denotes a significant between-group 
difference (+ and - IL-1β for a given t-BOOH concentration) as determined 
via two-way ANOVA followed by Bonferroni’s test for multiple comparisons 
(n = 7-16 from three separate dissections; p ≤ 0.0013). 
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Figure 13: IL-1β pre-treatment of mixed culture protects both 
astrocytes and neurons. Mixed cultures consisting of neurons and 
astrocytes from CD-1 mice were washed twice with treatment media and 
incubated with IL-1β (10 ng/mL) or vehicle for 48 h after which they were 
treated with 1.5 mM t-BOOH for 2.75 h. Cell death was determined 
qualitatively by fluorescence microscopy after terminating the toxicity 
experiment via washing thrice with PBS followed by treatment with 
propidium iodide (10 µg/mL). Representative photos depict phase contrast 
(left panel) and propidium iodide staining (right panel). 
Phase Contrast Propidium Iodide 
50 µm 
CTRL 
Vehicle+ t-BOOH 
IL-1β + t-BOOH 
Full Kill 
(Calphostin C) 50 µm 
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Figure 14: Increase in extracellular GSH in chimeric culture is 
astrocyte IL-1R1-dependent. Wild-type neurons were plated on 
astrocytes from il1r1 +/+ or -/- mice. Mixed cultures were washed twice 
with treatment media and incubated with IL-1β (10 ng/mL) or vehicle for 48 
h after which total supernatant GSH levels were measured. Data are 
expressed as mean μM GSH/well + SEM. An asterisk (*) denotes 
significant between-group difference (+ and – IL-1β within the same 
combination of chimeric culture) as assessed by two-way ANOVA followed 
by Bonferroni’s test for multiple comparisons. (n =8 from two separate 
dissections; p = 0.001). 
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Figure 15: IL-1β pre-treatment protects neurons plated on il1r1 +/+ 
but not il1r1 -/- astrocytes in chimeric mixed culture against t-BOOH-
mediated cell death. Astrocytes from either il1r1 +/+ or -/- mice, plated 
with neurons from CD-1 wild-type mice were washed twice with treatment 
media and incubated with IL-1β (10 ng/mL) or vehicle for 48 h after which 
they were treated with 1.5 mM t-BOOH for 1.25-1.5 h. This was followed 
by determination of toxicity by obtaining supernatant from the wells and 
measurement of LDH release for cell death (B and D) as well as addition 
of MTT to assess for cell survival (A and C). MTT incubation = 2 h. For 
MTT, data are expressed as mean cell survival + SEM normalized to non-
treated control cultures (= 100%). For LDH, data are expressed as mean 
cell death + SEM normalized to the Calphostin C-treated group (= 100%). 
An asterisk (*) denotes significant between-group difference (+ and – IL-
1β with or without t-BOOH) and a pound (#) denotes significant within-
group difference (+ and – IL-1β treated) as assessed by two-way ANOVA 
followed by Bonferroni’s test for multiple comparisons. [n=24-26 (A and B), 
n=18-22 (C and D); p < 0.0001]. 
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Figure 16: Attenuation of astrocytic GSH extrusion decreases 
cellular viability in mixed culture upon t-BOOH treatment. Mixed 
cultures derived from CD-1 mice (n = 8 from three separate dissections) 
were washed twice with treatment media and incubated with different 
concentrations of MK-571 as indicated for 2 h, after which the wells were 
treated with IL-1β (10 ng/mL) or vehicle for an additional 24 h. (A) Total 
supernatant GSH levels expressed as mean μM/well + SEM (B) Mean % 
cell survival normalized to MTT values of the non-treated control cultures 
(= 100%) following challenge with 1.5 mM t-BOOH for 2.45 h. An asterisk 
(*) denotes significant between-group difference (+ and – IL-1β with or 
without MK-571) and a pound (#) denotes significant within-group 
difference (+ and – IL-1β treated) as assessed by two-way ANOVA 
followed by Bonferroni’s test for multiple comparisons. Significance was 
assessed at p < 0.05.   
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Figure 17: Supplementation of pure neurons with GSH-Ethyl Ester 
(GEE) does not affect the cell viability upon t-BOOH treatment. 
Neurons from CD-1 mice were washed twice with treatment media and 
incubated with increasing concentrations of Glutathione-Ethyl ester (GEE). 
(A) Total intracellular GSH levels expressed as mean μmol GSH per gram 
of protein (n = 4-8). An asterisk (*) denotes values different from control (0 
mM GEE) as determine by one-way ANOVA followed by Dunnett’s t-test 
(p = 0.0013) (B). Mean % cell survival normalized to MTT values of the 
non-treated control cultures (= 100%) following exposure to 2 mM t-BOOH 
for 3 h (n = 3-6). An asterisk (*) denotes significant between-group 
difference (+ and -t-BOOH for a given concentration of GEE) and a pound 
(#) denotes significant within-group difference (+ and – t-BOOH) as 
determined by two-way ANOVA followed by Bonferroni’s test for multiple 
comparisons. (p < 0.0001). 
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Chapter 4. Discussion 
Oxidative stress and neuroinflammation have been found to coexist in a number 
of debilitating diseases [156-158]. Models that combined oxidative stress and 
endogenous neuroinflammation were used in the study. We specifically aimed to 
determine whether the neuroinflammatory cytokine IL-1β is inherently protective 
against an oxidant stress effected using t-BOOH, and if so, whether GSH was 
the predominant mediator of this effect. 
The results of the work are as follows:  
1) t-BOOH causes a concentration-dependent cell death in both neurons and 
astrocytes. 
2) IL-1β enhances GSH and confers protection against t-BOOH to astrocytes 
cultured alone but not to neurons in isolation. 
3) IL-1β enhances GSH in mixed cortical cell culture and confers protection 
against t-BOOH to both neurons and astrocytes in co-culture. 
4) Astrocytic signaling is required to observe IL-1β-mediated GSH increase and 
neuroprotection. 
5) Blocking the astrocytic release of GSH abrogates protection conferred to 
mixed cultures. 
6) Addition of the GSH analogue, GEE, at concentrations that are not toxic to 
the cells, does not elevate neuronal GSH levels, nor does it provide the 
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neurons any protection form t-BOOH toxicity. Hence, we can draw no 
conclusions regarding the role of GSH supplementation using this paradigm. 
Oxidative stress has been implicated as a contributory factor to neuronal damage 
in many neurological diseases and pathologies [159, 160]. These same 
disorders/diseases also show a component of a neuroinflammatory response 
[161-163]. Inflammatory response can be causative or reparative depending on 
the interplay of various cellular pathways. IL-1β has been shown to be a ‘master 
regulator’ of neuroinflammation [164]. IL-1β has been at the crossroads of repair 
and injury [6, 11, 63, 165]. Studies from our laboratory have shown both 
protective and detrimental effects of IL-1β. It was shown that IL-1β potentiates 
hypoxic neuronal injury in in vitro and in vivo models of cerebral ischemia. The 
il1r1 null mice showed smaller infarcts and less neurological deficits. In vitro, IL-
1β exacerbated hypoxia-induced neuronal death [67]. IL-1β-mediated regulation 
of astrocytic system xc- is responsible for its excitotoxic effects under hypoxic 
conditions [149]. In contrast, IL-1β was glioprotective against direct oxidative 
injury, in a glutathione-dependent fashion [1]. Given that the glioprotective 
potential of IL-1β was established in this study, we wanted to examine if IL-1β 
could alleviate oxidative stress in neurons. Since, the brain has a high oxygen 
demand and is rich in lipids, it vulnerable to injury by oxidants. Peroxides 
facilitate lipid peroxidation; hence we chose an organic peroxide, t-BOOH, a 
stressor previously used in several models of oxidative stress [166, 167].  
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Initial studies were devised to confirm previous findings of the laboratory, firstly 
that treatment of astrocytes with IL-1β increase in GSH production (Figure 3) [1]. 
This is in agreement with studies on non-neural cell types showing an 
association between IL-1β and GSH [168, 169]. However, in rat astrocytes, 
intracellular levels of GSH were shown to decrease following IL-1β exposure 
[170]. Similar results were demonstrated in a human glioma cell line [171]. The 
depletion of GSH in these studies was attributed to the production of oxidative 
stress occurring secondary to IL-1β treatment [170, 171]. In contrast, using the 
GSH:GSSG ratio as a proxy for the cells redox potential/oxidant status [172] as 
well as direct measurement of ROS, our laboratory found that IL-1β does not 
contribute to oxidative stress in murine astrocytes [1]. Overall, GSH levels in 
astrocytes can be regulated at multiple levels either affecting the enzymes, 
substrates or transporters [131]. 
Secondly, we confirmed that the increase in GSH is accompanied by 
glioprotection when IL-1β-treated astrocytes are exposed to t-BOOH (Figure 4) 
[1]. GSH has been reported to protect astrocytes against various insults [173-
175]. 
Thirdly, the enhancement of GSH and consequent glioprotection is occluded in 
the absence of IL-1R1 (Figure 5) [1]. This indicates that our IL-1β preparation is 
devoid of contaminants (e.g., LPS) and that the observed effect is exclusively 
due to IL-1β signaling through the IL-1R1.  
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Finally, the fact that MK-571 concentration-dependently hindered the release of 
GSH from astrocytes under both basal and IL-1β-stimulated conditions (Figure 
6A) suggests that Mrp1 transporter is involved in the GSH release, as has been 
demonstrated previously [1, 144, 155]. We had hypothesized that block of GSH 
release would prevent the glioprotective effect of IL-1β. However, the toxicity of t-
BOOH and the protection afforded by IL-1β pre-treatment was not appreciably 
affected by MK-571 (Figure 6B).  
The ability of IL-1β to enhance GSH production and to protect astrocytes in 
isolation from oxidant injury, did not extend to neurons cultured alone (Figure 7, 9 
and 10). Interestingly, other studies have shown cultured neurons to have a 
bivalent response to IL-1β. For instance, Rothwell and Strijbos showed that IL-1β 
in the range of 0.5-1 µg/ mL is neuroprotective against NMDA-induced toxicity; 
however, in the range of 10-100 µg/ mL, it exacerbates injury in rat neuronal cell 
cultures [63]. 
The data suggested that IL-1β-stimulated astrocytes but not neurons make GSH 
and are protected against oxidative stress and this might not be surprising 
considering that recycling of GSH and its constituents between the astrocytes 
and neurons has been deemed important for antioxidant homeostasis in the CNS 
[142, 176]. It has been demonstrated that neuronal GSH levels are lower than 
astrocytic GSH [124] rendering them more susceptible to oxidative injury. It was 
found that neurons co-cultured with astrocytes have higher levels of glutathione 
than neurons cultured alone, suggesting that astrocytes enhance the antioxidant 
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levels [143]. Astrocyte-conditioned medium has a high amount of extracellular 
GSH. The dipeptides CysGly and γ-GluCys are products of GSH breakdown and 
they can serve as precursors for glutathione synthesis in the neurons. Cysteine is 
a rate-limiting substrate for GSH synthesis and it has been shown to be derived 
from astrocytes for the neuronal GSH homeostasis [145, 146]. Zhang et al 
showed that bone marrow stromal cells modulate the redox status of chronic 
lymphocytic leukaemia (CLL) cells and promote cellular survival by beneficial 
interaction leading to enhanced GSH synthesis [177]. We proposed that a similar 
interaction may take place between astrocytes and neurons in our model.  
This led to investigation of response of mixed cultures to IL-1β treatment. We 
determined the GSH status of mixed cultures after IL-1β pre-treatment to find that 
there is enhancement in the extracellular GSH congruent with the results derived 
from astrocytes (Figure 11). Enhancement of GSH coincides with protection 
against t-BOOH-induced stress (Figure 13) that can be abrogated by inhibiting 
Mrp1-mediated GSH release by astrocytes using MK-571 (Figure 16). This 
pinpoints towards the synergy between astrocytes and neurons to maintain 
antioxidant homeostasis. Others have determined IL-1β to protect against 
excitotoxins in mouse mixed cortical cell cultures. Here they attribute the 
protection to the production of Nerve Growth Factor, but never looked at GSH 
levels or its potential to contribute [178]. 
Additional studies in slice culture demonstrate that IL-1β at similar concentrations 
to those used herein (10 ng/ mL) protected neurons against excitotoxicity and 
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oxygen/glucose deprivation-induced neuronal cell death [65]. Studies by 
Bernardino et al have also shown the biphasic effect of IL-1β by using mouse 
hippocampal slice cultures. It was shown that low dose (1 ng/ mL) of IL-1β 
potentiated AMPA-induced toxicity, whilst high dose (10 ng/ mL) of IL-1β 
significantly reduced the AMPA-induced toxicity [179]. In vivo, in a transgenic 
mouse model of Alzheimer’s disease, 4 weeks of induced overexpression of IL-
1β in the hippocampus reduced amyloid pathology also suggesting a protective 
role [4].  
PI staining enabled us to qualitatively check for injury and neuroprotection in 
mixed cultures. Both neurons and astrocytes in t-BOOH-treated wells were 
stained with PI, establishing that both the cell-types in mixed culture were 
susceptible to oxidant injury (Figure 13). Further studies involving double 
immunolabeling for markers selective for neurons and astrocytes in mixed culture 
could help compare the extent of neuroprotection rendered by IL-1β to each type 
of cell.  
Once we deciphered neuroprotection in mixed culture, we wanted to study any 
cell-specificity of response to IL-1β treatment of mixed cultures. Chimeric cultures 
were used for this purpose (Figure 14). Neurons when plated on il1r1 +/+ 
astrocytes but not on il1r1 -/- astrocytes showed an increase in GSH, as we 
expected. This supported the hypothesis that astrocytes form the basis of the 
observed neuroprotection in co-cultures. Chimeric co-cultures were then 
challenged with 1.5 mM t-BOOH and it was observed that the presence of 
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astrocytic signaling is required for protection against cell death (Figure 15). 
Interestingly, you will note that the viability of MTT assay appears slightly lesser 
when compared to the LDH readings. This is likely because the MTT assay 
requires incubation for at least two hours until the formazan crystals are formed 
(allowing for ongoing cell death) whereas LDH samples are read out immediately 
after termination of the experiment [153]. Although not shown in this thesis, 
others have determined that astrocyte-mediated support to neurons is lost upon 
glutathione depletion, again highlighting, the intricate interaction between 
neurons and astrocytes [123, 180, 181]. 
Lastly, we wanted to employ a model that mimics astrocyte-neuron redox 
coupling but allows for studying neurons in isolation to confirm whether GSH is 
the sole mediator of observed protection. As such, we set out to determine 
whether supplementing neurons in culture with GEE could substitutes for 
astrocyte-mediated enhancement of GSH levels. GEE has been shown to 
increase cellular GSH, circumventing the regulation of GSH biosynthesis [182]. 
Other have demonstrated that 0.5 mM GEE protects neurons from amyloid β 
toxicity (10 µM, 24 h) when pre-treated for one hour [183]. GEE (1–10mM, 24h) 
produced a dose-dependent elevation in GSH in rat mesencephalic cultures. The 
same study also showed that administration of 0.1–50mg/kg/d GEE to rats for 28 
days, either subcutaneously or via an implanted cannula, up-regulated the GSH 
levels in the brain and protected neurons in a Parkinson’s disease model [182]. 
GEE has been shown to be rapidly taken up and converted to GSH by tissues 
such as kidney, liver, spleen, pancreas and heart [184]. In our experiment, 
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treatment of the cultures with 0.3 – 3 mM GEE for 15 h, resulted in a significant 
increase in the intracellular GSH at 3 mM only (Figure 17A). Unfortunately, 
toxicity was observed at concentrations of 3 mM; and no effect on cell viability 
against t-BOOH- mediated stress was observed with the lower, non-toxic 
concentrations (Figure 17B). Hence, we cannot infer much from this model under 
the given paradigm. 
Overall, our findings suggest that neuroprotection against t-BOOH in the given 
model may be dependent on GSH and/or other factors provided by the 
astrocytes to neurons. Astrocytes release a variety of trophic factors under 
normal conditions that assist neuronal survival and conduction after injury to the 
brain [185]. Future studies involving transwell co-culture of astrocytes and 
neurons aimed at studying the effect of IL-1β observed in mixed culture would 
provide direct evidence for whether neurons require physical contact with 
astrocytes for enjoying neuroprotection. Transwell co-culture can be recruited to 
study the exchange taking place between astrocytes and neurons that may be 
aiding neurons against oxidative damage. 
In conclusion, this study confirms that IL-1β is neuroprotective and brings about 
an increase in glutathione in astrocytes and mixed cultures; however, the 
protection observed along with a concomitant increase GSH, necessitates the 
presence of astrocytes and a functional astrocytic IL-1R1 receptor. Interestingly, 
the lab has studied dichotomy in the action of IL-1β. We can therefore infer that 
the final outcome may protective, neutral or inimical, depending on but not limited 
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to its site of release, concentration, the environmental niche of the cells and the 
effector cell [165]. A better understanding of the physiological and 
pathophysiological consequences and the underlying mechanisms of IL-1β 
signaling in the CNS may serve the emergence of strategies to utilize its 
reparative potential. 
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Chapter 5. Future Directions 
We deciphered the neuroprotective potential of IL-1β signaling that was found to 
be localized to astrocytes. Along with t-BOOH, it would be interesting to assess 
neuroprotection against other stressors such iron [186] and malonate [187]. 
Intracellular iron potentiates oxidative toxicity. Malonate leads to striatal specific 
injury and has been used as a model of Huntington’s disease. Thus far, we have 
studied cortical cell cultures in vitro; however, it would be reasonable to test the 
response of striatal cell cultures to IL-1β and malonate injury. This would be 
beneficial in comparing results from cortical as well as striatal regions of the 
brain. 
We have successfully demonstrated IL-1β-mediated protection via cell viability 
assays and qualitatively through PI staining. A quantitative analysis of markers of 
oxidative stress in mixed cultures would add to our existing findings. A previous 
study in the field has shown that t-BOOH treatment of rat hepatocytes causes 
generation of malondialdehyde and 8-hydroxydeoxyguanosine (8-OHdG) which 
are markers of oxidative stress [188]. These could be quantified in models 
involving mixed culture to complement results from cell viability assays. 
Analysis of the astrocyte-conditioned medium can also help assess whether 
astrocytes release precursors for GSH synthesis in neurons. Another study that 
would corroborate our findings would be qRT-PCR (Real-Time Quantitative 
Reverse Transcription PCR) for the enzyme GSH peroxidase after IL-1β 
stimulation of astrocytes and neurons individually in culture. 
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Additionally, it would be interesting to study in vivo models addressing similar 
questions. The hypothesis that IL-1R1 null animals are more susceptible to 
oxidative injury than wild type control animals could be tested and findings be 
compared to the results from in vitro experiments. Previous studies have shown 
a strong linkage between excitotoxicity and oxidative stress which co-appear in 
several CNS disorders. NMDA is an excitotoxin known to increase oxidative 
stress. Model of NMDA-induced oxidative stress could be used for this aim and 
the role of endogenous IL-1β in conditions of oxidative stress could be assessed. 
Intra-cortical NMDA microinjections would enable us to carry out histological 
analysis and assess the extent of injury between il1r1 +/+ and -/- animals. 
Similarly, in vivo malonate models could be employed to study the hypothesis 
that IL-1R1 null mice are more susceptible to in vivo oxidative stress-mediated 
neurodegeneration. Behavioral studies such as Open field test [189] and rotarod 
test [190] would add another dimension what has been studied so far. 
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